The research team is using a custom automation platform operated by Green Button Go™ Automation Scheduling and Data Integration Software to screen 14,000 compounds that have already been approved by the FDA for therapeutic potential against COVID-19.
“The world is in a race to save lives,” said Biosero CEO Tom Gilman. “I expect that pairing the expertise of Scripps Institute researchers with Biosero’s state-of-the-art lab automation will double the speed at which Scripps scientists can process drug therapy candidates.”
Dr. Thomas Rogers, Assistant Professor of Medicine, and Dr. Dennis Burton, Co-Chair Department of Immunology and Microbiology, at Scripps Research Institute, are leading research to optimize screening assays that test the inhibition of active SARS-CoV-2 virus infection by known compounds. To do so, Calibr, the drug development division of Scripps Research, is leveraging ReFRAME, a drug repurposing collection. ReFRAME contains 14,000 compounds approved by the FDA for other diseases or that ...
